Results 251 to 260 of about 86,601 (293)

Trends in US Hematology/Oncology Physician Perceptions and Referral Practices for Hematopoietic Cell Transplant: A National Survey Conducted by NMDP

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background To evaluate trends in allogeneic hematopoietic cell transplant (HCT) referral perceptions and practices, we compared surveys of Hematology‐Oncology (Hem‐Onc) physicians conducted in 2015 (N = 150), 2019 (N = 302), and 2024 (N = 183) and reported changes over time.
Aye Mon Thida, Ankita Shah, Kelley Frederick (Steffens), Samantha Watters, Mingqian Duan, Steven Devine, Susan T. Vadaparampil, Joseph Pidala   +7 more
wiley   +1 more source

Correlates and Detection of Digital Health Literacy in Patients With Colorectal Carcinoma or Non-Hodgkin Lymphoma: Cross-Sectional Study.

JMIR Cancer
Gunning TS, Khoudary A, Billini O, Ip A, Sorgen L, Marshall J, Weinberg BA, Potosky AL, Schwartz MD, Conley CC, Derry-Vick HM.   +10 more
europepmc   +1 more source

Persistent Respiratory Symptoms Post-COVID-19 in a Non-Hodgkin Lymphoma Patient: A Case Report. [PDF]

Cureus
Dimeas IE, Papra S, Dimeas G, Pantazopoulos I, Daniil Z.   +4 more
europepmc   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial. [PDF]

Sci Rep
Surakijboworn M, Polprasert C, Wudhikarn K, Rojnuckarin P, Uaprasert N.   +4 more
europepmc   +1 more source

Prognostic implication of serum levels of IL-6 and IL-10 in children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma. [PDF]

BMC Cancer
Zeng C, Wei Z, Huang J, Zhu J, Sun F, Wang J, Lu S, Zhang Y, Sun X, Zhen Z.   +9 more
europepmc   +1 more source

Blood virome profiling reveals subtype-specific viral signatures and reduced diversity in non-Hodgkin lymphoma. [PDF]

Virulence
Pan S, Li W, Zhao X, Wang H, Liu J, Zhang W, Zhou C, Xie Y.   +7 more
europepmc   +1 more source

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. [PDF]

J Clin Oncol
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen RR, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson CA.   +22 more
europepmc   +1 more source

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial. [PDF]

Cancers (Basel)
Joffe E, Kumar A, Tuscano JM, Moskowitz AJ, Owens C, Noy A, Palomba ML, Zelenetz AD, Ni A, Sharon E, Vardhana S.   +10 more
europepmc   +1 more source

Frailty Trajectories and Influencing Factors in Patients With Non-Hodgkin Lymphoma During Chemotherapy: Protocol for a Longitudinal Mixed Methods Study.

JMIR Res Protoc
Du R, Zhang Y, Yang H, Du Y, Li J, Zhang B.   +5 more
europepmc   +1 more source